Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week High After Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s share price reached a new 52-week high during mid-day trading on Wednesday after Royal Bank Of Canada raised their price target on the stock from $191.00 to $195.00. Royal Bank Of Canada currently has an outperform rating on the stock. Jazz Pharmaceuticals traded as high as $192.66 and last traded at $192.7220, with a volume of 1408011 shares. The stock had previously closed at $173.83.

A number of other analysts have also issued reports on JAZZ. Needham & Company LLC raised their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Piper Sandler reiterated an “overweight” rating and issued a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. UBS Group reissued a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Finally, Bank of America raised their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $213.85.

Insider Activity

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the transaction, the chief accounting officer owned 7,012 shares in the company, valued at $1,200,454.40. This represents a 39.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 4.30% of the company’s stock.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat: Jazz reported Q4 revenue of ~$1.20B and EPS of $6.64, topping consensus and showing year-over-year revenue growth driven by neuroscience and oncology products. JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
• Positive Sentiment: Strong oxybate/Xywav growth is a core driver of the beat and underpins management’s optimism for 2026. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: 2026 revenue outlook raised: management projects $4.25B–$4.50B for 2026 while highlighting progress on rare-disease and oncology launches — a bullish forward signal. Jazz projects 4.25B–4.50B 2026 revenue
• Positive Sentiment: Multiple analyst price-target upgrades and bullish ratings after the print (Bank of America, Wells Fargo, Morgan Stanley, RBC) lift forward sentiment and imply substantial upside from current levels. Analyst price target raises TickerReport: BofA raise
• Neutral Sentiment: Detailed context available in the earnings call transcript and investor presentation for pipeline, launch timing and margin assumptions. Investors may want to review these for items that affect long-term modeling. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Near-term pullback/volatility drivers: the stock ran up into the print (near its 52‑week high), trading volume is elevated, and some investors are likely taking profits despite the beat — a plausible reason for the intraday decline.
• Negative Sentiment: Structural/valuation considerations: Jazz still has leverage on the balance sheet and reported a negative net margin in the background data; some investors may be cautious on margins and cash flow conversion as the company invests in launches. (See earnings coverage for metrics.) Earnings Call Summary

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its stake in shares of Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after acquiring an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after acquiring an additional 7,954 shares during the last quarter. Focus Partners Wealth increased its position in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after purchasing an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 4.0%

The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.44 and a current ratio of 1.86. The business’s 50 day moving average price is $169.18 and its 200-day moving average price is $150.86. The firm has a market cap of $11.63 billion, a price-to-earnings ratio of -31.65, a price-to-earnings-growth ratio of 1.06 and a beta of 0.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $6.51 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% on a year-over-year basis. Equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.